Kiniksa Pharmaceuticals International, plc 8-K

What Happened

• On February 24, 2026, Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 8-K under Item 2.02 to report results of operations and financial condition and furnished a press release announcing its financial results for the fiscal year ended December 31, 2025 (Exhibit 99.1). The filing was signed by Douglas Barry, Senior Vice President, Chief Legal Officer and Secretary.

Key Details

• Item reported: 2.02 — Results of operations and financial condition (press release furnished).
• Press release date: February 24, 2026; period covered: fiscal year ended December 31, 2025.
• Exhibit furnished: 99.1 (press release). The filing also includes the interactive XBRL cover page (Exhibit 104).
• The 8-K does not report executive changes, mergers/acquisitions, or other material events beyond the financial-results press release.

Why It Matters

• The filing notifies investors that Kiniksa has publicly released its fiscal 2025 earnings/financial results; those results (revenue, net income/loss, cash and operating metrics) can affect valuation and near-term trading.
• Retail investors should review the press release (Exhibit 99.1) for the detailed figures and management commentary and watch for the company’s upcoming Form 10-K or earnings presentation for audited results and fuller disclosure.